Abstract: A process includes, in a computer system, acquiring a first measurement that corresponds to a software container. Acquiring the measurement includes a hardware processor of the computer system measuring a given layer of a plurality of layers of layered file system structure corresponding to the software container. The given layer includes a plurality of files, and the first measurement includes a measurement of the plurality of files. The process includes storing the first measurement in a secure memory of the computer system. A content of the secure memory is used to verify an integrity of the software container.

Abstract: A system and method for intelligent message routing is provided. The system and method include a) storing, in one or more storage devices, a plurality of transmission rules for transmitting messages, b) receiving a message to be transmitted to a participant, c) comparing the message to the plurality of transmission rules, d) determining a first channel to transmit the message to a computer device associated with the participant based on the comparison, e) converting the message into a first message for transmission on the first channel, and f) transmitting the first message over the first channel.

Abstract: The present invention relates to the therapeutic uses of compositions containing antibody molecules and functional fragments thereof, e.g antibody molecules and functional fragments capable of binding to tumor necrosis factor alpha (TNF?), in the topical treatment of inflammatory bowel diseases, including Crohn's disease and ulcerative colitis.

Abstract: A novel form of tile leveling system is disclosed which is made of a metallic material and used for aligning and leveling tiles as they are laid in floors, walls, countertops, or the like. The device has a locking assembly and a bottom plate combined with a shaft that extends from the bottom plate through the locking assembly so that the locking assembly is movable along the length.

Abstract: The present invention relates to the therapeutic uses of compositions containing antibody molecules and functional fragments thereof, e.g antibody molecules and functional fragments capable of binding to tumor necrosis factor alpha (TNF?), in the topical treatment of inflammatory bowel diseases, including Crohn's disease and ulcerative colitis.

Abstract: In a delayed release formulation comprising a core containing a drug and a delayed release coating for providing intestinal release, release of the drug in the colon is accelerated by including an isolation layer between the core and the delayed release coating. The delayed release coating comprises an inner layer and an outer layer. The outer layer comprises a pH dependently soluble polymeric material which has a pH threshold at about pH 5 or above. The inner layer comprises a soluble polymeric material which is soluble in intestinal fluid or gastrointestinal fluid, said soluble polymeric material being selected from the group consisting of a polycarboxylic acid polymer that is at least partially neutralised, and a non-ionic polymer, provided that, where said soluble polymeric material is a non-ionic polymer, said inner layer comprises at least one additive selected from a buffer agent and a base.

Abstract: In a delayed release formulation comprising a core containing a drug and a delayed release coating for providing intestinal release, release of the drug in the colon is accelerated by including an isolation layer between the core and the delayed release coating. The delayed release coating comprises an inner layer and an outer layer. The outer layer comprises a pH dependently soluble polymeric material which has a pH threshold at about pH 5 or above. The inner layer comprises a soluble polymeric material which is soluble in intestinal fluid or gastrointestinal fluid, said soluble polymeric material being selected from the group consisting of a polycarboxylic acid polymer that is at least partially neutralised, and a non-ionic polymer, provided that, where said soluble polymeric material is a non-ionic polymer, said inner layer comprises at least one additive selected from a buffer agent and a base.

Abstract: The present invention relates to a modified release coated capsule and a process to obtain that capsule.

Abstract: Herein described is a modified release coated capsule and a process to obtain that capsule.

Abstract: A roof tent closure system designed to facilitate the opening and closing of tent equipment. Both halves of the roof box—front and rear—are equipped with two profiles along the edge and perimeter: the front profile and the rear profile. The front profile is fitted with a locking groove. In turn, the rear profile is fitted with an inward-facing oblique skirt. This oblique skirt, under pressure, slots into the locking groove. A push button is located on the rear profile. Pressing the push button releases the oblique skirt from the locking groove, thereby opening the roof tent.

Abstract: The present invention relates to a modified release coated capsule and a process to obtain that capsule.

Abstract: In a delayed release formulation comprising a core containing a drug and a delayed release coating for providing intestinal release, release of the drug in the colon is accelerated by including an isolation layer between the core and the delayed release coating. The delayed release coating comprises an inner layer and an outer layer. The outer layer comprises a pH dependently soluble polymeric material which has a pH threshold at about pH 5 or above. The inner layer comprises a soluble polymeric material which is soluble in intestinal fluid or gastrointestinal fluid, said soluble polymeric material being selected from the group consisting of a polycarboxylic acid polymer that is at least partially neutralised, and a non-ionic polymer, provided that, where said soluble polymeric material is a non-ionic polymer, said inner layer comprises at least one additive selected from a buffer agent and a base.

Abstract: Systems and methods for balancing levels of liquid fuel among multiple vehicle-mounted fuel tanks utilize at least one control valve that is configured to admit pressurized gas into a first fuel tank while a second fuel tank is ventilated, responsive to detection of a difference of liquid fuel levels within the first and second fuel tanks. Admission of pressurized gas into one fuel tank and ventilation of another fuel tank creates a pressure imbalance that causes liquid fuel to flow through a balancing line connecting the fuel tanks. Balancing may be performed in a bidirectional manner.

Abstract: Systems and methods for balancing levels of liquid fuel among multiple vehicle-mounted fuel tanks utilize at least one control valve that is configured to admit pressurized gas into a first fuel tank while a second fuel tank is ventilated, responsive to detection of a difference of liquid fuel levels within the first and second fuel tanks. Admission of pressurized gas into one fuel tank and ventilation of another fuel tank creates a pressure imbalance that causes liquid fuel to flow through a balancing line connecting the fuel tanks. Balancing may be performed in a bidirectional manner.

Abstract: In a delayed release formulation comprising a core containing a drug and a delayed release coating for providing intestinal release, release of the drug in the colon is accelerated by including an isolation layer between the core and the delayed release coating. The delayed release coating comprises an inner layer and an outer layer. The outer layer comprises a pH dependently soluble polymeric material which has a pH threshold at about pH 5 or above. The inner layer comprises a soluble polymeric material which is soluble in intestinal fluid or gastrointestinal fluid, said soluble polymeric material being selected from the group consisting of a polycarboxylic acid polymer that is at least partially neutralised, and a non-ionic polymer, provided that, where said soluble polymeric material is a non-ionic polymer, said inner layer comprises at least one additive selected from a buffer agent and a base.

Abstract: The present invention relates to the therapeutic uses of compositions containing antibody molecules and functional fragments thereof e.g antibody molecules and functional fragments capable of binding to tumor necrosis factor alpha (TNF?), in the topical treatment of inflammatory bowel diseases, including Crohn's disease and ulcerative colitis.

Abstract: The present invention relates to a delayed release pharmaceutical formulation for delivering an active agent to the intestine, a method of preparing such formulation and the use of such formulation in the treatment of gastrointestinal disorders.

Abstract: In a delayed release formulation comprising a core containing a drug and a delayed release coating for providing intestinal release, release of the drug in the colon is accelerated by including an isolation layer between the core and the delayed release coating. The delayed release coating comprises an inner layer and an outer layer. The outer layer comprises a pH dependently soluble polymeric material which has a pH threshold at about pH 5 or above. The inner layer comprises a soluble polymeric material which is soluble in intestinal fluid or gastrointestinal fluid, said soluble polymeric material being selected from the group consisting of a polycarboxylic acid polymer that is at least partially neutralized, and a non-ionic polymer, provided that, where said soluble polymeric material is a non-ionic polymer, said inner layer comprises at least one additive selected from a buffer agent and a base.